Production (Stage)
Tevogen Bio Holdings Inc.
TVGN
$1.31
$0.086.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.73% | 574.26% | 133.81% | 288.05% | 790.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.91% | 365.99% | 161.74% | 293.64% | 1,169.92% |
| Operating Income | 64.91% | -365.99% | -161.74% | -293.64% | -1,169.92% |
| Income Before Tax | -192.03% | -160.02% | -50.68% | 56.44% | 136.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -192.03% | -160.02% | -50.68% | 56.44% | 136.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -192.03% | -160.02% | -50.68% | 56.44% | 136.63% |
| EBIT | 64.91% | -365.99% | -161.74% | -293.64% | -1,169.92% |
| EBITDA | 65.00% | -374.39% | -164.52% | -299.05% | -1,190.27% |
| EPS Basic | -185.10% | 39.88% | -6.77% | 78.69% | 129.85% |
| Normalized Basic EPS | 70.34% | 5.95% | -57.66% | -203.88% | -894.12% |
| EPS Diluted | 73.10% | 39.88% | -6.77% | 78.37% | -1.52% |
| Normalized Diluted EPS | 69.25% | 5.95% | -57.66% | -203.88% | -858.82% |
| Average Basic Shares Outstanding | 17.53% | 331.03% | 41.81% | 28.47% | 14.44% |
| Average Diluted Shares Outstanding | 13.36% | 331.03% | 41.81% | 28.47% | 18.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |